These tests, such as the Myriad MyChoice® CDx and FoundationOne® CDx tests, have been approved by regulatory agencies as companion diagnostics for PARP inhibitor treatment in patients with ovarian and prostate cancer [6, 8, 15, 16]. Here, PARP1 is linked to prostate carcinoma.